Cyclooxygenase-2 expression in human gliomas: Prognostic significance and molecular correlations

Cancer Research

Volumn 61, Issue 11, 2001, Pages 4375-4381

  Shono, T ^a   Tofilon, P J ^a   Bruner, J M ^a   Owolabi, O ^a   Lang, F F ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; PROTEIN BCL 2; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN; TUMOR MARKER;

ADULT; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER SURVIVAL; GENE OVEREXPRESSION; GENE SEQUENCE; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGRESSION ANALYSIS; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; ANTIGENS, NUCLEAR; ASTROCYTOMA; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLOOXYGENASE 2; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; KI-67 ANTIGEN; MEMBRANE PROTEINS; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTO-ONCOGENE PROTEINS C-BCL-2; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035360795     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Cyclooxygenase-2 inhibitors in tumorigenesis (part I)
2. Cyclooxygenase in biology and disease
3. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
4. Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: Possible physiological and therapeutic implications
5. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue
6. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-α and phorbol ester
7. Cyclooxygenase-2 inhibitors in tumorigenesis (part II)
8. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer
9. Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: Evidence for growth suppression by inhibiting COX-2 expression
10. Cyclooxygenase-2 expression in human esophageal carcinoma
11. Prostaglandin and thromboxane synthesis by human intracranial tumors
12. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal anti-inflammatory drugs
13. Cyclooxygenase-2 expression is abundant in alveolar type II cells in lung cancer-sensitive mouse strains and in premalignant lesions
14. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas
15. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas
16. Expression of cyclooxygenase-2 in prostate carcinoma
17. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer
18. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: Evidence for a transcriptional effect
19. Cyclooxygenase-2 expression in human adenocarcinoma cell line HT29 cl.19A
20. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck
21. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas
22. Combined antitumor effect of radiation and ibuprofen in human prostate carcinoma cells
23. Prostaglandins in human brain tumors
24. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
25. Expression of cyclooxygenase-1 and -2 in human colorectal cancer
26. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells
27. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas
28. Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma
29. The relationship between cyclooxygenase-2 expression and colorectal cancer
30. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
31. Colorectal cancer risk, chronic illnesses, operations, and medications: Case control results from the Melbourne Colorectal Cancer Study
32. Aspirin use and reduced risk of fatal colon cancer
33. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis
34. Suppression of intestinal polyposis in Apc Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
35. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis
36. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent
37. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction
38. Inhibition of cyclooxygenase-2 gene expression by p53
39. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
40. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
41. Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line
42. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo
43. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases
44. Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of bax and translocation of mitochondrial cytochrome c independent of COX-2 expression
45. Mutational and nonmutational activation of p21ras in rat colonic azoxymethane-induced tumors: Effects on mitogen-activated protein kinase, cyclooxygenase-2, and cyclin D1
46. Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: Prognostic factors and long-term outcome
47. Pathways leading to glioblastoma multiforme: A molecular analysis of genetic alterations in 65 astrocytic tumors
48. Patterns of cyclooxygenase-1 and -2 expression in human gliomas in vivo
49. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398
50. Prognostic significance of p53 immunoreactivity in patients with glioma
51. Correlation of p53 immunoreactivity and sequencing in patients with glioma
52. Mutations of the p16 gene in gliomas
53. Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas
54. Patterns of expression of Rb and p16 in gliomas and correlation with survival
55. Bcl-2 expression in cerebellar medulloblastomas
56. p53 protein immunostaining in routinely processed paraffin-embedded sections
57. Proliferation index as a predictor of prognosis in malignant gliomas of childhood
58. Expression of bcl-2 in reactive and neoplastic astrocytes: Lack of correlation with presence or degree of malignancy
59. bcl-2 protein expression in tumors of the central nervous system
60. Human gliomas with wild-type p53 express bcl-2
61. Cyclooxygenase-2 is induced globally in infarcted human brain
62. Spreading depression and focal brain ischemia induce cyclooxygenase-2 in cortical neurons through N-methyl-D-aspartic acid-receptors and phospholipase A2
63. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: Independence from COX-2 protein expression
64. Evidence for involvement of cyclooxygenase-2 in proliferation of two gastrointestinal cancer cell lines
65. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2
66. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions
67. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer
68. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma
69. High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas
70. p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma
71. Clonal expansion of p53 mutant cells is associated with brain tumour progression
72. Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells
73. Enhancement of prostaglandin E2 production by epidermal growth factor requires the coordinate activation of cytosolic phospholipase A2 and cyclooxygenase 2 in human squamous carcinoma A431 cells
74. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
75. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor